number of access : ?
number of downloads : ?
ID 116118
Author
Bando, Hiroshi Tokushima University|Integrative Medicine Japan KAKEN Search Researchers
Keywords
Inclisrian statin dyslipidemia
LDL-C
Atherosclerotic cardiovascular disease (ASCVD)
Content Type
Journal Article
Description
Up-to-date pharmacological topics for inclisiran and statin for dyslipidemia are described. The efficacy of inclisiran has been reported for reduction of LDL-C values. Inclisiran has been involved in gene silencing, which brings selective inhibition of a protein by targeting its mRNA. For RCTs of inclisiran, ORION 10/11 studies were conducted, where inclisiran and control groups were followed 1.5 years. LDL-C reduced in 53.8%/49.2%. RCTs of 19 meta-analyses showed whether statins will prolong life and its degree. As a result, statin can delay onset of events compared to placebo for cardiovascular death 9.3 days, myocardial infarction 18 days, and stroke 6.1 days.
Journal Title
SunText Review of Endocrine Care
Publisher
SunText Reviews
Volume
1
Issue
1
Start Page
104
Published Date
2021-06-30
Rights
This is an open-access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI (Published Version)
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences